Illustration of amyloid plaques (orange) among brain cells
Science Photo Library/Alamy
In early July, the US Food and Drug Administration (FDA) approved a treatment called donanemab for people with early-stage Alzheimer’s disease. It is the second drug shown to slow the condition’s progression, and the third FDA-authorised medication that clears the amyloid proteins that accumulate in the brains of people with Alzheimer’s.
The FDA’s approval of three new drugs – donanemab, lecanemab and aducanumab – in just over three years has led some to declare a leap forward in Alzheimer’s disease treatment. Japan, South Korea, China,…
By . Experience three performances from the Roma Heroes International Theatre Festival from Rome, Italy…
As time passes, both throughout the regular season and as years themselves pass, there are…
BTCPay Server issued an emergency update to fix five security flaws in Nginx, urging operators…
From a new adaptation of Harry Potter to Netflix's take on Pride and Prejudice Source…
These resources are intended to help teachers find reading passages, help students practice word recognition…
Mia Wurgaft and Jake Horowitz in The Charioteer, at the Cell. Photo: Austin Ruffer If…